Literature DB >> 24927728

Hsp90 modulates PPARγ activity in a mouse model of nonalcoholic fatty liver disease.

Matthew C Wheeler1, Nicholas Gekakis1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent complication of obesity, yet cellular mechanisms that lead to its development are not well defined. Previously, we have documented hepatic steatosis in mice carrying a mutation in the Sec61a1 gene. Here we examined the mechanism behind NAFLD in Sec61a1 mutant mice. Livers of mutant mice exhibited upregulation of Pparg and its target genes Cd36, Cidec, and Lpl, correlating with increased uptake of fatty acid. Interestingly, these mice also displayed activation of the heat shock response (HSR), with elevated levels of heat shock protein (Hsp) 70, Hsp90, and heat shock factor 1. In cell lines, inhibition of Hsp90 function reduced Pparγ signaling and protein levels. Conversely, overexpression of Hsp90 increased Pparγ signaling and protein levels by reducing degradation. This may occur via a physical interaction as Hsp90 and Pparγ coimmunoprecipitated in vivo. Furthermore, inhibition of Hsp90 in Sec61a1 mutant hepatocytes also reduced Pparγ protein levels and signaling. Finally, overexpression of Hsp90 in liver cell lines increased neutral lipid accumulation, and this accumulation was blocked by Hsp90 inhibition. Our results show that the HSR and Hsp90 play an important role in the development of NAFLD, opening new avenues for the prevention and treatment of this highly prevalent disease.
Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  heat shock protein 90; heat shock response; peroxisome proliferator-activated receptor γ; steatosis

Mesh:

Substances:

Year:  2014        PMID: 24927728      PMCID: PMC4109764          DOI: 10.1194/jlr.M048918

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  36 in total

1.  Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.

Authors:  María Eugenia Miquilena-Colina; Elena Lima-Cabello; Sonia Sánchez-Campos; María Victoria García-Mediavilla; Miguel Fernández-Bermejo; Tamara Lozano-Rodríguez; Javier Vargas-Castrillón; Xabier Buqué; Begoña Ochoa; Patricia Aspichueta; Javier González-Gallego; Carmelo García-Monzón
Journal:  Gut       Date:  2011-01-26       Impact factor: 23.059

Review 2.  Signalling through nuclear receptors.

Authors:  Jamshed R Tata
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

Review 3.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

4.  Triglyceride accumulation protects against fatty acid-induced lipotoxicity.

Authors:  Laura L Listenberger; Xianlin Han; Sarah E Lewis; Sylvaine Cases; Robert V Farese; Daniel S Ory; Jean E Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

5.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

Authors:  Kimihiko Matsusue; Martin Haluzik; Gilles Lambert; Sun-Hee Yim; Oksana Gavrilova; Jerrold M Ward; Bryan Brewer; Marc L Reitman; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  Hsp90 chaperones PPARγ and regulates differentiation and survival of 3T3-L1 adipocytes.

Authors:  M T Nguyen; P Csermely; C Sőti
Journal:  Cell Death Differ       Date:  2013-10-04       Impact factor: 15.828

7.  Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90.

Authors:  Joseph M Jez; Julian C-H Chen; Giulio Rastelli; Robert M Stroud; Daniel V Santi
Journal:  Chem Biol       Date:  2003-04

8.  IRE1α-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis.

Authors:  Shiyu Wang; Zhouji Chen; Vivian Lam; Jaeseok Han; Justin Hassler; Brian N Finck; Nicholas O Davidson; Randal J Kaufman
Journal:  Cell Metab       Date:  2012-10-03       Impact factor: 27.287

9.  Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass.

Authors:  Birgit Knebel; Jutta Haas; Sonja Hartwig; Sylvia Jacob; Cornelia Köllmer; Ulrike Nitzgen; Dirk Muller-Wieland; Jorg Kotzka
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

10.  ERAD and protein import defects in a sec61 mutant lacking ER-lumenal loop 7.

Authors:  Thomas Tretter; Fábio P Pereira; Ozlem Ulucan; Volkhard Helms; Susanne Allan; Kai-Uwe Kalies; Karin Römisch
Journal:  BMC Cell Biol       Date:  2013-12-06       Impact factor: 4.241

View more
  11 in total

1.  Heat Shock Protein 90 Modulates Lipid Homeostasis by Regulating the Stability and Function of Sterol Regulatory Element-binding Protein (SREBP) and SREBP Cleavage-activating Protein.

Authors:  Yen-Chou Kuan; Tsutomu Hashidume; Takahiro Shibata; Koji Uchida; Makoto Shimizu; Jun Inoue; Ryuichiro Sato
Journal:  J Biol Chem       Date:  2016-12-21       Impact factor: 5.157

2.  The total flavonoids from Selaginella tamariscina (beauv.) Spring improve glucose and lipid metabolism in db/db mice.

Authors:  Xiaolan Wang; Aozi Feng; Peipei Yuan; Yang Fu; Zhiyao Bai; Ning Zhou; Xiaoke Zheng
Journal:  Iran J Basic Med Sci       Date:  2020-10       Impact factor: 2.699

Review 3.  Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic Disorders.

Authors:  Ping Ren; Yuquan Zhang; Yan Huang; Yingli Yang; Ming Jiang
Journal:  Clin Med Insights Oncol       Date:  2015-04-27

4.  Changes of signal transductivity and robustness of gene regulatory network in the carcinogenesis of leukemic subtypes via microarray sample data.

Authors:  Cheng-Wei Li; Tzu-Ying Lai; Bor-Sen Chen
Journal:  Oncotarget       Date:  2018-05-04

5.  Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma.

Authors:  Philip Weidner; Michaela Söhn; Torsten Schroeder; Laura Helm; Veronika Hauber; Tobias Gutting; Johannes Betge; Christoph Röcken; Florian N Rohrbacher; Vijaya R Pattabiraman; Jeffrey W Bode; Rony Seger; Daniel Saar; Ariane Nunes-Alves; Rebecca C Wade; Matthias P A Ebert; Elke Burgermeister
Journal:  Oncogenesis       Date:  2020-06-10       Impact factor: 7.485

6.  Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway.

Authors:  Mu Zhang; Cheng Qian; Zu-Guo Zheng; Fei Qian; Yanyan Wang; Pyone Myat Thu; Xin Zhang; Yaping Zhou; Lifan Tu; Qingling Liu; Hui-Jun Li; Hua Yang; Ping Li; Xiaojun Xu
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

Review 7.  Implications of Mitochondrial Unfolded Protein Response and Mitokines: A Perspective on Fatty Liver Diseases.

Authors:  Hyon Seung Yi
Journal:  Endocrinol Metab (Seoul)       Date:  2019-03

8.  Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System.

Authors:  Zu-Guo Zheng; Xin Zhang; Xiao-Xiao Liu; Xiu-Xiu Jin; Lunzhi Dai; Hui-Min Cheng; Dan Jing; Pyone Myat Thu; Mu Zhang; Hongyang Li; Jing Zhu; Chang Liu; Bin Xue; Yu Li; Ligong Chen; Cheng Peng; Weiliang Zhu; Lin Wang; Junli Liu; Hui-Jun Li; Ping Li; Xiaojun Xu
Journal:  Theranostics       Date:  2019-08-12       Impact factor: 11.556

9.  Heat shock protein 70 promotes lipogenesis in HepG2 cells.

Authors:  Jielei Zhang; Nengguang Fan; Yongde Peng
Journal:  Lipids Health Dis       Date:  2018-04-10       Impact factor: 3.876

10.  Circulating Hsp90 Isoform Levels in Overweight and Obese Children and the Relation to Nonalcoholic Fatty Liver Disease: Results from a Cross-Sectional Study.

Authors:  Anca Bălănescu; Iustina Stan; Ioana Codreanu; Valentina Comănici; Eugenia Bălănescu; Paul Bălănescu
Journal:  Dis Markers       Date:  2019-12-03       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.